• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE ‐LY trial
ConclusionsAmongst the current clinical bleeding risk scores, the ORBIT score demonstrated the best discrimination and calibration. All the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin.
Source: Journal of Internal Medicine - November 7, 2017 Category: Internal Medicine Authors: M. Proietti, Z. Hijazi, U. Andersson, S. J. Connolly, J. W. Eikelboom, M. D. Ezekowitz, D. A. Lane, J. Oldgren, V. Roldan, S. Yusuf, L. Wallentin, Tags: Original Article Source Type: research

Comparison of Bleeding Risk Scores in Patients with Atrial Fibrillation:Insights from the RE ‐LY Trial
ConclusionsAmong the current clinical bleeding risk scores, the ORBIT score demonstrated the best discrimination and calibration. All the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin.This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - October 16, 2017 Category: Internal Medicine Authors: Marco Proietti, Ziad Hijazi, Ulrika Andersson, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Deirdre A. Lane, Jonas Oldgren, Vanessa Roldan, Salim Yusuf, Lars Wallentin, Tags: Original Source Type: research

Reply to “Important factors affecting the choice of an oral anticoagulant may be missed in database studies”
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 28, 2017 Category: Internal Medicine Authors: Anna Gundlund, Emil Loldrup Fosb øl, Jonas Bjerring Olesen Tags: Letter to the Editor Source Type: research

Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.
Source: Journal of Internal Medicine - September 21, 2017 Category: Internal Medicine Authors: L. Staerk, T. A. Gerds, G. Y. H. Lip, B. Ozenne, A. N. Bonde, M. Lamberts, E. L. Fosb øl, C. Torp‐Pedersen, G. H. Gislason, J. B. Olesen Tags: Original Article Source Type: research

Important factors affecting the choice of an oral anticoagulant may be missed in database studies
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 7, 2017 Category: Internal Medicine Authors: Emma Aarnio, Risto Huupponen, Maarit Jaana Korhonen Tags: Letter to the Editor Source Type: research

Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban, and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 1, 2017 Category: Internal Medicine Authors: Laila Staerk, Thomas A Gerds, Gregory Y H Lip, Brice Ozenne, Anders N Bonde, Morten Lamberts, Emil L Fosb øl, Christian Torp‐Pedersen, Gunnar H Gislason, Jonas B Olesen Tags: Original Article Source Type: research

A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation
The objective of this review is to provide an overview of modern AF stroke prevention with a focus on tailored treatment strategies. Biomarkers and genetic factors have been proposed to help identify ‘high‐risk’ patients to be targeted for oral anticoagulation, but ultimately their use must be balanced against that of more simple and practical considerations for everyday use. Current guidelines have directed focus on initial identification of ‘truly low‐risk’ patients with AF, that is those patients with a CHA2DS2‐VASc [congestive heart failure, hypertension, age ≥75 years (two points), diabetes mellitus, ...
Source: Journal of Internal Medicine - March 21, 2016 Category: Internal Medicine Authors: G. Y. H. Lip, T. Potpara, G. Boriani, C. Blomström‐Lundqvist Tags: Review Source Type: research

Tailored treatment strategies: a new approach for modern management of atrial fibrillation
Abstract Atrial fibrillation (AF) is not benign. Cardiovascular diseases and risk factors differ importantly amongst patients. Careful phenotyping with the aim to start tailored therapy may improve outcome and quality of life. Furthermore, structural remodelling plays an important role in initiation and progression of AF. Therapies that interfere in the remodelling processes are promising because they may modify the atrial substrate. However, success is still limited probably due to variations in the underlying substrate in individual patients. The most favourable effects of lifestyle changes on success of rhythm control h...
Source: Journal of Internal Medicine - March 16, 2016 Category: Internal Medicine Authors: I. C. Gelder, A. H. Hobbelt, E. G. Marcos, U. Schotten, R. Cappato, T. Lewalter, J. Schwieler, M. Rienstra, G. Boriani Tags: Review Source Type: research